Unlike most other adipokines, local and circulating levels of adiponectin decrease in obesity and related conditions, including insulin resistance, T2DM, endothelial dysfunction, hypertension, and atherosclerosis, all contributing to CVD in general and coronary heart disease in particular [3]. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.